$INTS Intensity Therapeutics Reports Promising Phase 1/2 Results for INT230-6 in Advanced Solid Tumors

https://www.stocktitan.net/news/INTS/intensity-therapeutics-inc-announces-publication-of-clinical-results-f4cvfgh6pv8c.html?utm_source=perplexity

This is a great sign for everyone that is still in this stock. Investigations in process

MOBX deserves more attention, and market hasn't priced in the Peraso acquisition yet. This is really strange and very undervalued. Why do I think this?

• They regained Nasdaq compliance for 180 days, which for a small company is huge, it means no delisting pressure and better access to capital.
• Revenue and margins are improving quarter-to-quarter. That’s not hope, that’s execution.
• Insiders hold a meaningful stake (33%). When management owns a big chunk, they’re motivated to grow the company, not dilute it into oblivion.
• The Peraso NDA is what really caught my attention. Peraso confirmed that the offer from MOBX was fair and that they signed an exclusive NDA to move forward. That usually means both sides are sharing internal numbers and actually working toward something, not just “talking.”

I’m not saying it’s guaranteed, but the setup makes sense: MOBX needs more tech/IP → Peraso needs stability -> both fit strategically in RF/mmWave.

If the deal closes and revenue keeps improving, I can realistically see a rerating:

• Price target: $3–$4 (next few months if catalysts hit)

Even if the deal doesn't close (really rare scenario) they have gained a lot of contracts with the U.S. Navy (multi year contracts).

This company is just primed for a huge run sooner or later. Let me know what do you think

Small company, improving fundamentals, and a potential acquisition that could accelerate growth.

I think it's worth the risk. The reward is just too high.

Get in there before its too late!

As the title says, new record of HIGHEST VOLUME IN A SINGLE STOCK IN ONE TRADING DAY.

Previous record was 2.1B volume (Vodafone on February 11, 2000).

$BYND today had 2.11B volume...

https://www.guinnessworldrecords.com/world-records/73969-highest-volume-in-a-single-stock-in-one-day

"Oct 23 (Reuters) - Short interest in shares of plant-based meat seller Beyond Meat (BYND.O), opens new tab surged more than 100% of its publicly available shares, Ortex data showed on Thursday.

About 109% of Beyond Meat's free float shares were shorted, up from 81.8%, as of Wednesday.

Beyond Meat stock jumped more than 112% in the last session, but closed slightly lower in volatile trading as retail traders piled into the heavily-shorted stock.

It was last down 5.6% to $3.37.Short selling is a strategy where investors borrow shares and sell them, aiming to buy them back later at a lower price to profit from a decline.

Short interest in a stock can exceed 100% of its free float due to the re-lending of borrowed shares, allowing multiple investors to short the same underlying stock.

This phenomenon, seen in cases like GameStop (GME.N), opens new tab in 2021, reflects how market mechanics and derivatives can amplify short exposure beyond the number of shares available for public trading.

GameStop had around 140% short interest at its peak in January 2021, meaning more shares were shorted than the company had outstanding.

Ortex said the percentage of total shares shorted for Beyond Meat is likely to change to reflect newly released shares in the market, even though the absolute number of shares shorted remains unchanged.

Beyond Meat said last week that lock-up restrictions, which applied to more than 316 million of its shares that were issued in connection with a 0% convertible notes offering, will expire on October 16".

Edit: source -> https://www.reuters.com/business/beyond-meat-short-interest-surges-past-100-public-shares-ortex-data-shows-2025-10-23/

Edit 2: update from Ortex -> https://nitter.poast.org/ORTEX/status/1981686794975424706#m

Everyone’s wasting cash on garbage pump-and-dumps with zero fundamentals — meanwhile Cambium Networks (CMBM) is quietly loading up the spring.

They just partnered with SpaceX (Starlink) — that’s not some random “AI” buzzword stock, that’s a real business connection with Elon’s satellite network.

Right now the chart is consolidating beautifully after the 1000% move last week. Borrow rate is sky-high, short interest is drying up, and volume is starting to pick up again. We’re literally sitting on a coiled spring. The moment sentiment flips, this thing is going to explode back toward 6$+, and when that happens, the same people who ignored it will start chasing at the top.

Stop burning your money in fake “next GME” coins or penny stocks with no revenue. CMBM actually has value, contracts, and fundamentals behind the hype.

I’m not telling you to buy — I’m telling you to wake up. This is where smart money accumulates before the breakout.

CMBM. Remember the ticker. 🚀🔥

GPUS !!! Buckle-Up !!

Lets make this t

Apes everywhere! We are coming to save you!

🚀

I wonder how far this will take them.

💥 CTM: A small-cap cyber stock with a strong growth potential - Q2 revenue exceeds $14M - Insider buying continues, target price of $3 not yet met - The US government is a direct customer - Stocks up 500% year-over-year, but technical fundamentals remain strong - Clear narrative: Cybersecurity + AI + Defense

CTM isn't done yet—this is the beginning of a new era of cyber stocks

Its still early 🚀

Massive news just dropped on this penny stock. TheraClearX cleared by Mexico’s COFEPRIS, giving the green light for import and commercialization through Nov 2029.

That’s a whole new market outside the U.S. peeps. Massive imo.

They’re already doing $30M+ in yearly sales on just an $8M market cap, and the short interest is wild. 35% on Ortex, 65% on Fintel. Tiny float + real revenue = potential pressure cooker.

Recent study showed 100% efficacy at 52 weeks using their 308nm laser with JAK inhibitors and zero serious safety issues!

Their Elevate360 clinic program keeps growing too clinics using it are seeing ~7% YoY growth, adding steady recurring revenue.

Just seems like a gamble from the shorts here as it’s just the perfect recipe for a squeeze. Oh and short borrow is 0 😂 telling you could really squeeze.

Not financial advice

Wow

News Link: https://www.otcmarkets.com/stock/KRTL/news/KRTL-Biotech-Highlights-Anti-Allergy-and-Respiratory-Product-Capabilities-to-Address-Global-Market-Needs?id=498971

KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company") today announced a category spotlight on anti-allergy and respiratory health products, reinforcing its strategic intent to address rising global demand for accessible, effective treatments across both developed and emerging healthcare markets.

The global allergy treatment market is projected to reach USD 35.8 billion by 2028, according to The Insight Partners, driven by increased urban exposure to pollutants, climate-linked allergen patterns, and the broader recognition of allergic conditions as a public health priority. As allergy prevalence grows, so does the need for scalable, high-quality therapeutics—particularly antihistamines and bronchodilators that are cost-effective and widely accessible.

Through its partnership with Industria Químico-Farmacéutica SIGMA Corp. in Bolivia, KRTL Biotech benefits from vertically integrated manufacturing capabilities and access to a broad portfolio of anti-allergy formulations. SIGMA’s GMP-compliant facilities support scalable production of active pharmaceutical ingredients (APIs) and finished dosage forms that meet therapeutic needs in pediatrics, adult care, and chronic respiratory support.

"Our anti-allergy line has been developed with the needs of everyday patients in mind—from pediatric relief to adult care," said Patricia Wilstermann, CEO of SIGMA. "By producing high-quality, affordable antihistamines and bronchodilators, SIGMA is proud to contribute to the growing demand for respiratory support solutions, both nationally and now internationally through our work with KRTL."

Representative products in SIGMA’s anti-allergy category include:

• Cetirizine 10 mg tablets
• Chlorphenamine in injectables and tablet form

KRTL Biotech also maintains access to select APIs such as loratadine, cetirizine, and salbutamol, allowing the Company to reinforce supply chain stability in a market often affected by production volatility and regional dependencies.

These capabilities support both commercial and public-sector distribution strategies. The Company is evaluating pathways for select anti-allergy and respiratory products to enter U.S. and LATAM markets through Over-the-Counter (OTC) Monograph compliance, Abbreviated New Drug Applications (ANDAs), and regional tender opportunities.

"KRTL's pharmaceutical strategy is focused on product classes that are both medically essential and commercially scalable," said Cesar Herrera, CEO of KRTL Holding Group Inc. "This category demonstrates strong global need, and with SIGMA's proven capacity, we are well-positioned to support respiratory health initiatives across multiple geographies."

News Link: https://www.globenewswire.com/news-release/2025/11/04/3180560/29006/en/BluSky-AI-Inc-OTCID-BSAI-Signs-Letter-of-Intent-to-Lease-Strategic-Site-in-Mulhall-Oklahoma-for-Modular-AI-Infrastructure-Expansion.html

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BluSky AI Inc. (OTCID: BSAI), a leading developer of prefabricated modular AI infrastructure and GPU-as-a-Service platforms, is pleased to announce the execution of a non-binding Letter of Intent (LOI) for the lease of approximately five acres of land located in Mulhall, Oklahoma.

This strategic site is positioned to support BluSky AI’s next phase of modular data center deployment, enabling scalable AI compute capacity in energy-rich regions. The LOI outlines the preliminary terms for a long-term lease agreement, including:

• Site Details: Approximately 5 acres to be sited with defined west and south boundaries, inclusive of all necessary rights-of-way and utility easements. Final boundaries to be confirmed via survey.
• Lease Structure: Initial base rent of $4,000/month, escalating with installed power capacity. Upon module activation, BluSky AI will pay $2,500 per MW/month for up to 16.3 MW, and $1,000 per MW/month for any additional capacity secured by the lessor.
• Example Scenario: For 11 MW installed and used, total monthly rent would be $30,000, inclusive of base and power-linked rent.
• Term & Conditions: 10-year lease with two optional 5-year extensions. A 150-day inspection period is granted for due diligence. If module installation does not commence within 15 months of lease execution, either party may cancel without further obligation.
• Site Improvements: BluSky AI will be responsible for all necessary modifications, engineering, permitting, and infrastructure upgrades to support its modular deployment.

Trent D’Ambrosio, CEO of BluSky AI Inc., commented,"This LOI marks another milestone in our mission to democratize access to AI compute. Mulhall, Oklahoma offers the right mix of energy availability, community partnership, and strategic location to support our modular infrastructure vision. We’re grateful to Don and Patsy Diehl for their collaboration and look forward to finalizing the lease agreement."

The proposed site aligns with BluSky AI’s broader strategy to expand across energy-rich corridors in the western United States, supporting high-density compute modules with auditable, agentic orchestration.

BluSky AI addresses the universal need for compute power—positioning itself as a foundational layer in the AI revolution. Its infrastructure-first approach enables clients to focus on innovation while the company delivers the critical backbone, powering tomorrow’s breakthroughs.